EMD-63071
SARS-CoV-2 spike glycoprotein trimer in prefusion form (1-RBD up state)
EMD-63071
Single-particle3.49 Å
Deposition: 10/01/2025Map released: 02/04/2025
Last modified: 25/06/2025
Sample Organism:
Severe acute respiratory syndrome coronavirus 2
Sample: SARS-CoV-2 spike glycoprotein
Deposition Authors: Fukuhara H
,
Anraku Y ,
Kita S ,
Maenaka K
Sample: SARS-CoV-2 spike glycoprotein
Deposition Authors: Fukuhara H
,
Anraku Y ,
Kita S ,
Maenaka K
ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4 + and CD8 + T-cell responses and neutralizing antibody induction.
Kawakita T ,
Sekiya T,
Kameda Y,
Nomura N,
Ohno M ,
Handabile C,
Yamaya A,
Fukuhara H ,
Anraku Y ,
Kita S ,
Toba S,
Tsukamoto H,
Sawa T,
Oshiumi H,
Itoh Y ,
Maenaka K ,
Sato A ,
Sawa H,
Suzuki Y ,
Brown LE ,
Jackson DC,
Kida H ,
Matsumoto M,
Seya T ,
Shingai M
(2025) J Virol , 99 , e0229024 - e0229024
,
Sekiya T,
Kameda Y,
Nomura N,
Ohno M ,
Handabile C,
Yamaya A,
Fukuhara H ,
Anraku Y ,
Kita S ,
Toba S,
Tsukamoto H,
Sawa T,
Oshiumi H,
Itoh Y ,
Maenaka K ,
Sato A ,
Sawa H,
Suzuki Y ,
Brown LE ,
Jackson DC,
Kida H ,
Matsumoto M,
Seya T ,
Shingai M
(2025) J Virol , 99 , e0229024 - e0229024
Grant Support:
- Japan Agency for Medical Research and Development (AMED): JP20ae0101047 (Japan)
- Japan Agency for Medical Research and Development (AMED): JP21fk0108463 (Japan)
- Japan Agency for Medical Research and Development (AMED): JP22ama121037 (Japan)
- Japan Agency for Medical Research and Development (AMED): JP223fa627005 (Japan)
- Japan Science and Technology: JPMJCR20H8 (Japan)
- Japan Society for the Promotion of Science (JSPS): JP20H05873 (Japan)